Immune Aging and The Key Biomarkers of Longevity

In this detailed long copy article, Dr Craige Golding discusses the concept of immune aging, immunosenescence and inflammaging. Cellular and molecular changes in innate and adaptive immunity with age. and why it matters.  

Key concepts of immune aging discussed

The post is based on a lecture by the author, longevity medical  specialist, founder of the Golding Institute Dr Craige Golding.

• Clinical Impact: Increased infections, poor vaccination responses, autoimmunity, chronic diseases
• Biomarkers of Immune Age: Inflammatory markers (e.g. IL-6), immune cell ratios (CD4:CD8, NLR), iAge clock, cell subset clocks, metabolic indicators
• Intervention Strategies: Pharmacological approaches (mTOR inhibitors, metformin, etc.) and lifestyle modifications (exercise, diet) to slow or reverse immune aging
• Future Directions: Emerging therapies and research models to rejuvenate the immune system (organised per the latest evidence)

What is immune aging

We’ll begin by defining immune aging and its two hallmark processes – immunosenescence (the decline in immune function) and inflammaging (chronic low-grade inflammation) – and discuss why these are clinically relevant.

We’ll then delve into mechanistic changes that occur in the immune system as we age, covering both innate and adaptive arms. Next, we examine the clinical consequences of an aged immune system: higher infection rates (e.g. COVID-19 severity in elderly), reduced vaccine efficacy, increased autoimmunity, and links to chronic diseases (like cardiovascular disease or dementia).

We will then identify key biomarkers of immune aging – from lab markers (cytokines, immune cell counts) to advanced composite “immune age clocks” (like the inflammatory aging clock iAge and immune cell proportion clocks) – explaining how these biomarkers reflect biological age and predict health outcomes.

Finally, we discuss evidence-based interventions to mitigate immune aging: drugs (such as mTOR inhibitors that enhance vaccine response in older adults) and lifestyle measures (exercise, nutrition, etc. that can rejuvenate certain immune functions).

We will also touch on emerging research (like organoid models for immune aging) to highlight future therapies. Each section will be supported by current research findings, with speaker notes elaborating details and citations for credibility. Let’s begin by understanding what immune aging entails and why it’s crucial for medical practice.

Core Concepts and Definitions

• Immunosenescence: Gradual decline in immune function with age (affects both innate & adaptive responses)
• Inflammaging: Persistent low-level inflammation in older adults (due to senescent cells, chronic infections, etc.)
• These processes are intertwined – an aged immune system shows reduced pathogen defence and heightened inflammatory signaling
• Thymic involution: Shrinking of the thymus from puberty onward leading to fewer new T cells, a driver of immunosenescence
• Immune risk profile: Phenotype in very old age with poor immunity – e.g. low naive T cells, inverted CD4:CD8 ratio – associated with morbidity

Understanding immunosenescence

Immunosenescence refers to the aging-related deterioration of the immune system’s ability to fight infections and respond to new antigens.

This involves both the innate immune system (immediate responders like neutrophils, macrophages, NK cells) and the adaptive immune system (T and B lymphocytes that provide specific immunity). With age, these cells become less effective: for example, older individuals produce fewer naïve T cells (due to thymic involution, the thymus gland shrinking and producing less new T cells) and have an accumulation of “experienced” or senescent T cells. In parallel, inflammaging occurs – a state of chronic, smouldering inflammation in the elderly. Inflammaging is partly driven by senescent cells secreting inflammatory cytokines (the SASP, senescence-associated secretory phenotype), long-term antigenic load (e.g. CMV infection), and age-related micro-environmental changes. It manifests as elevated serum markers like IL-6, TNF-α and C-reactive protein in many older adults. Notably, immunosenescence and inflammaging fuel each other: a declining immune system fails to clear senescent or infected cells, leading to more inflammatory stimuli, which in turn further impairs immunity. Clinically, researchers sometimes define an “immune risk profile” for the elderly – for instance, an inverted CD4/CD8 T-cell ratio (more CD8^+^ than CD4^+^ cells) is a known biomarker of immune aging and has been correlated with higher mortality and frailty in older populations. We will see how these concepts translate into functional changes and health outcomes in the next sections.

Why Immune Aging Matters Clinically

• Higher infection rates: Older adults suffer more frequent and severe infections (e.g. >80% of COVID-19 deaths were in ≥60-year-olds).
• Atypical presentations: Immune aging alters symptom profiles (e.g. UTIs in elderly often lack localising symptoms).
• Poor vaccine responses: Reduced antibody titres and protection (necessitating high-dose or adjuvanted vaccines for ≥65 age group).
• Increased autoimmunity: Aging immune system becomes prone to self-reactivity (e.g. late-onset rheumatoid arthritis, shingles).
• Onset of cancers: Declining immune surveillance allows higher cancer incidence in the elderly.

An aged immune system has real consequences for patients

Infectious diseases hit older adults harder: for example, during the COVID-19 pandemic, over 80% of deaths occurred in those over 60. Similarly, common infections like pneumonia, urinary tract infections, and shingles occur more frequently and with greater complications in the elderly. Moreover, presentations can be atypical – an older patient with a serious UTI may not mount a high fever or local urinary symptoms due to a blunted immune response, often presenting primarily with confusion or general decline. This can delay diagnosis.

Vaccine responses also wane with age: older adults show significantly lower seroconversion rates and antibody titres after vaccination. For instance, an influenza vaccine study showed markedly weaker antibody responses in the elderly compared to young adults. Chronic inflammation (inflammaging) can disrupt the immune activation needed for effective vaccination. This is why special strategies are used – e.g., high-dose flu vaccines or adding adjuvants (immune stimulants) to vaccines for older patients to improve efficacy. Despite such measures, older patients often remain less protected, leading to breakthrough infections.

Auto-Immune Diseases

Immune aging also contributes to autoimmune diseases. The aged immune system, with accumulations of memory T and B cells and a pro-inflammatory milieu, can lose tolerance to self. For example, increased autoantibodies are observed in older adults. Diseases like giant cell arteritis or late-onset rheumatoid arthritis are thought to be facilitated by immune aging – one reason these are predominantly diseases of older people. Mechanistically, age-related B cell changes (like emergence of age-associated B cells and reduced regulatory mechanisms) lead to more autoreactive antibodies, and senescent T cells can encourage inflammation that damages tissues.

Finally, cancer incidence rises with age partly because of waning immune surveillance. Young immune systems can often detect and eliminate nascent tumour cells (via NK cells and cytotoxic T lymphocytes). In older adults, those cells are fewer and less functional – e.g. aged CTLs and NKs produce less perforin and granzymes needed to kill tumour cells, and express fewer activating receptors like NKG2D. Combined with a pro-tumour inflammatory environment (high IL-6, TNF-α, etc. can promote cancer growth), this leads to increased cancer risk.

It’s noteworthy that immune checkpoint inhibitors (like anti-PD-1 therapies) are less effective in some older patients, partly because there are simply fewer competent T cells to revive. In summary, immune aging is a critical factor behind many geriatric syndromes – understanding it helps us manage infections, tailor vaccines, monitor for autoimmunity, and consider cancer prevention in our older patients.

Mechanistic Drivers of Immune Aging

• Thymic involution: ~90% reduction in thymus size by age 60; lowers naïve T cell output (especially CD8^+^ naïve T cells).
• Haematopoietic stem cell (HSC) aging: HSCs become biased toward myeloid lineage and undergo clonal expansions (e.g. CHIP – clonal haematopoiesis). Leads to fewer lymphocytes and chronic inflammation.
• Chronic antigenic load: Lifelong exposures (e.g. CMV, periodontal infections) drive continuous immune activation → exhaustion of T cells and accumulation of senescent cells.
• Senescent cells & SASP: Accumulation of senescent immune cells (e.g. CD8^+^CD28^–^ T cells) that secrete pro-inflammatory cytokines (SASP), perpetuating inflammaging.
• Metabolic dysregulation: Aging immune cells shift metabolism (e.g. T cells become more glycolytic) and dysfunctional mitochondria trigger inflammasome activation (increases IL-1β, IL-6 production).

What drives immunosenescence and inflammaging

Several biological processes drive immunosenescence and inflammaging. A central factor is thymic involution – the thymus (where T cells mature) shrinks and largely turns to fat by late adulthood. By age 60, thymic tissue is minimal, severely reducing the output of new naïve T cells. This disproportionately affects CD8^+ T cells (cytotoxic T cells), since residual homeostatic proliferation partly maintains CD4^+ naïve T cell counts. The result is a smaller pool of naïve T cells to respond to novel infections or vaccines, a hallmark of immunosenescence.

In the bone marrow, haematopoietic stem cells (HSCs) undergo aging changes too. Aged HSCs show myeloid skewing – they preferentially produce myeloid cells (neutrophils, monocytes) at the expense of lymphoid cells. They also accumulate mutations and clones (a phenomenon known as clonal haematopoiesis of indeterminate potential, CHIP). These HSC clones often have mutations in epigenetic regulators (e.g. TET2, DNMT3A) that give them a proliferative advantage. While these clones expand, they are often functionally abnormal and pro-inflammatory, contributing to systemic inflammation and higher risks of malignancies and cardiovascular disease. Essentially, the blood-forming stem cell compartment tilts towards producing cells that drive inflammaging.

Viruses

Chronic antigen exposure is another driver. Persistent viruses like cytomegalovirus (CMV) are infamous for “aging” the immune system. CMV, present in many elders, continuously stimulates T cells, leading to a high proportion of CMV-specific memory T cells that crowd out the naive T-cell repertoire. The immune risk profile identified in very old individuals (inverted CD4:CD8 ratio, expansion of CD8^+CD28^- T cells) strongly correlates with CMV positivity. Other chronic stimuli include latent tuberculosis, repeated respiratory infections, and even chronic periodontal disease or gut microbe imbalances – all sustaining an inflammatory environment.

The accumulation of senescent cells is both a result and cause of immune aging. Senescent immune cells (like some T cells, NK cells) no longer proliferate or function properly but release a variety of pro-inflammatory factors – this is the SASP (senescence-associated secretory phenotype). For example, late-stage differentiated T cells that have lost costimulatory CD28 (CD8^+CD28^- cells) secrete more inflammatory cytokines and can actually inhibit other immune responses. They create a feedback loop: more inflammation → further immune cell dysfunction → more cells entering senescence.

Lastly, metabolic changes in aging immune cells play a role. As cells age, their metabolism shifts – often towards less efficient or aberrant pathways. Aged T cells, for instance, become more dependent on glycolysis and show mitochondrial dysfunction. This can activate intracellular sensors like the NLRP3 inflammasome (which responds to mitochondrial debris and metabolic stress), leading to release of IL-1β and IL-18 – adding to inflammaging. There’s also a systemic aspect: older individuals often have insulin resistance or higher glucose/lipid levels, which can aggravate immune cell aging (high glucose can cause more pro-inflammatory monocytes, etc.). The net effect is a vicious cycle of metabolic dysregulation and immune dysfunction.

In summary, immune aging is driven by both intrinsic factors (thymic decline, HSC aging, telomere attrition in lymphocytes) and extrinsic factors (chronic infections, environmental inflammation). These lead to a remodeled immune landscape that we’ll now detail in terms of specific cell types.

Innate Immune Changes with Age

• Monocytes/Macrophages: Fewer classical monocytes in blood and reduced phagocytic function. Aged macrophages secrete more IL-6, TNF-α, IL-1β and less IL-10 (pro-inflammatory tilt).
• Neutrophils: Impaired bacterial killing (less effective NET formation, oxidative burst); delayed resolution of inflammation (linger in tissues causing damage).
• Dendritic Cells: Diminished antigen presentation and interferon production. Aged dendritic cells produce fewer antiviral signals and contribute to weaker vaccine responses.
• Natural Killer (NK) Cells: Increased total NK cell number but functional decline. Fewer cytotoxic granules (perforin) and lower receptor expression → reduced killing of virus-infected and tumour cells.
• Sex differences: Men over ~65 often show higher innate inflammatory activity and relatively lower adaptive responses than women of same age.

The innate immune system

The innate immune system is our first line of defence – undergoes significant age-related alterations:

• Monocytes and macrophages: The blood of older adults shows a decline in classical monocytes (the standard patrol monocytes), although some inflammatory subsets of monocytes can increase. Tissue macrophages in an older person become less efficient “garbage collectors.” Normally, macrophages engulf and clear pathogens, senescent cells, and debris. In elderly individuals, macrophages exhibit reduced phagocytic capacity – they don’t clear bacteria or dead cells as effectively, leading to lingering inflammation. At the same time, aged macrophages shift their cytokine production: they overproduce pro-inflammatory cytokines like TNF-α, IL-6, IL-1β and underproduce anti-inflammatory IL-10. This tip towards a pro-inflammatory state contributes to chronic tissue inflammation (for example, older men with severe COVID-19 had highly inflammatory monocyte responses). Also, older monocyte/macrophage populations tend to have hyperactive inflammasome signaling (NLRP3), partly due to mitochondrial dysfunction, which further amplifies IL-1β production.
• Neutrophils: These frontline cells (key in bacterial infection) also decline in function. While neutrophil counts might remain normal, their functionality does not. Chemotaxis (movement to infection sites) can be impaired in elderly due to altered receptor expression (e.g., downregulated CXCR2 means neutrophils respond less to chemoattractants). Aged neutrophils produce fewer reactive oxygen species and form weaker NETs (neutrophil extracellular traps), making bacterial killing less effective. They also have delayed apoptosis and clearance, so they hang around in tissues longer, potentially causing bystander damage and sustained inflammation.
• Dendritic cells (DCs): These are the bridge between innate and adaptive immunity (presenting antigens to T cells). In older adults, DC numbers may not drastically drop, but their function is blunted. Studies show aged DCs produce lower amounts of interferon-α in response to viruses, and present antigens less effectively to T cells. As a result, T cells are not optimally activated. This contributes to the known weaker vaccine responses; for instance, plasmacytoid DCs in an older person might fail to stimulate T cells strongly, leading to poor antibody production after a flu shot. Additionally, aged DCs show increased tendency to react to self-antigens (loss of tolerance), which may promote autoimmunity.
• Natural Killer cells: NK cells actually can increase in number with age (compensatory or due to more IL-15 signaling), but paradoxically their cytotoxic function declines. “Memory-like” NK cell expansions (CD57^+ NK cells) accumulate – these are long-lived NK cells that have seen battle and are less proliferative. Aged NKs have reduced expression of activating receptors (like NKG2D) and release less perforin and granzymes on encountering a target. This means an older person’s NK cells are less efficient at destroying virus-infected cells and surveilling for tumours. Indeed, impaired NK activity is one reason for increased viral reactivations (like shingles) and perhaps cancer incidence. There’s evidence that the environment of an aged body makes NK cells less responsive (experiments in mice show young NKs become less effective when transferred into an old mouse).

The differences between sexes

To highlight, research also notes sex differences: older males often show a more pronounced pro-inflammatory innate profile (higher monocyte and NK cell activation), whereas females maintain slightly better adaptive responses into old age. This could be why older men sometimes have worse outcomes in infections like COVID-19 (more inflammatory damage).

Overall, the innate immune changes boil down to an immune system that’s on a slow burn of inflammation but ironically less capable of quickly and effectively clearing an acute threat.

Adaptive Immune Changes with Age: T Cells

• Naïve T cell decline: Marked reduction in naïve T cells, especially CD8⁺, due to thymic involution. Remaining naïve T cells show impaired proliferation and IL-2 production.
• Memory T cell expansion: Accumulation of memory and “aged-associated” T cells (e.g. CD8⁺^+^ GZMK⁺ effector T cells) that exhibit exhaustion markers (PD-1, TOX) and secrete inflammatory mediators.
• Senescent T cells: Increase in CD28^–^ late-stage T cells (especially CD8^+^). These cells are hyporesponsive and can suppress immune responses, associated with chronic infections & cancer risk
• CD4^+^ T cell polarization: Skewing toward pro-inflammatory Th17 over Th1/Th2. Regulatory T cells (Tregs) increase in number but can become dysfunctional (senescent Tregs).
• Reduced TCR diversity: Shrinking T-cell receptor repertoire – many “holes” in immune coverage for new antigens. Confirmed by TCR sequencing in elderly (fewer unique TCR clones).
• T lymphocytes undergo profound changes with aging, fundamentally altering adaptive immunity.

T-Cells

• The total number of T cells might not drop dramatically (some subsets even expand), but their composition shifts. Naïve T cells – which are key to responding to novel pathogens or vaccines – decline steadily. This is primarily due to thymus shrinkage; by age 70, one’s supply of new T cells is a trickle. Studies show a sharp decrease in CD8^+ naïve T cells with age, while CD4^+ naïve T cells are somewhat better preserved (thanks to homeostatic proliferation, the body tries to maintain them). However, even the naive T cells that remain are less functional: aged naive CD4^+ T cells, for instance, proliferate poorly and produce less IL-2 when stimulated, meaning they cannot expand robustly to new challenges.
• Meanwhile, memory T cells accumulate. Decades of exposures lead to large pools of memory cells for past infections. In the elderly, we see an expansion of late-stage effector memory T cells. There’s a particular subset termed “age-associated T cells” – identified by markers like granzyme K (GZMK) in CD8^+ T cells. These cells express exhaustion markers PD-1 and TOX, indicating they’ve been repeatedly stimulated and are now semi-functional. They actually secrete pro-inflammatory factors (like GZMK itself can induce inflammation). GZMK^+ CD8 T cells in older adults are thought to drive inflammaging by interacting with senescent cells (e.g., GZMK can induce more SASP from senescent cells). So, paradoxically, some memory T cells in elders might do more harm than good by sustaining inflammation.
• We also observe a rise in senescent T cells, often characterized by loss of CD28 (a costimulatory receptor needed for full T cell activation). CD8^+CD28^- T cells increase significantly with age. These cells are sometimes called “late differentiated” or TEMRA cells; they can no longer divide and have shortened telomeres. Functionally, they’re often cytotoxic but dysregulated – they can produce inflammatory cytokines and even interfere with other immune cells. For example, CD28^- T cells can inhibit dendritic cell function and crowd the immune space. Clinically, an expanded CD28^- T-cell population is linked with poorer outcomes: studies correlate it with chronic viral infections (CMV, HIV), increased cancer incidence, and frailty. It’s essentially a biomarker of immune aging (part of the immune risk profile).
• CD4^+ T helper cells also change in quality. There’s evidence of a shift in differentiation: aged CD4 T cells more often become Th17 cells (which produce IL-17, driving inflammation and autoimmunity) at the expense of the balanced Th1/Th2 responses. This means older immune systems may inadvertently favor pathways that contribute to tissue inflammation (e.g. Th17 can promote autoimmunity). Interestingly, Regulatory T cells (Tregs) – which normally suppress autoimmunity – actually increase in number with age, possibly as a compensatory mechanism. However, these Tregs may themselves become senescent/dysfunctional: aged Tregs tend to shift to more glycolytic metabolism and can lose suppressive capacity. Dysfunctional Tregs could allow more auto-reactive cells to escape control, contributing to autoimmunity and also potentially to reduced immune surveillance of tumors (since balanced regulation is off). There’s also a newly described subset of cytotoxic CD4^+ T cells (expressing Eomes, Granzyme B, perforin) that increase with age. Intriguingly, these cytotoxic CD4 cells are found at higher levels in supercentenarians (extremely old but healthy individuals), which might represent an adaptive change – perhaps providing some antiviral or anti-tumour protection in late life.
• A crucial consequence of all this is the loss of T-cell receptor (TCR) diversity. Throughout life, we accumulate many memory T cells specific to past infections, and we lose naive cells that could recognize new ones. By advanced age, the breadth of unique TCRs in circulation is much narrower. High-throughput sequencing confirms older individuals have “holes” in their TCR repertoire – entire segments of potential antigen recognition are missing. This is why new pathogens (like emerging viruses) or even novel antigens in cancers pose a big threat to seniors – their immune system simply doesn’t have the T cells needed to recognize many of these new targets. It also explains why vaccines are less effective and need optimization for older adults.

In summary, the T-cell compartment in elderly patients is like an army with many veterans (memory cells) some of whom are exhausted or rogue, and very few new recruits (naïve cells) coming in. It’s an army that’s seen a lot but is less adaptable to new challenges.

Adaptive Immune Changes with Age: B Cells

• Decline in naïve B cells & diversity: Fewer new B cells from bone marrow, plus reduced immunoglobulin diversity. Older adults have a restricted B cell receptor (BCR) repertoire (less ability to recognise novel antigens).
• Impaired antibody quality: Diminished class-switching and affinity maturation in germinal centres. Leads to lower antibody titres and weaker neutralisation (e.g. influenza vaccine yields lower protective antibodies in elderly).
• Autoantibodies: Increased production of autoantibodies with age. Mechanism: reduced expression of Autoimmune Regulator (AIRE) in aging leads to less elimination of self-reactive B cells in the marrow/thymus.
• Age-associated B cells (ABC): Accumulate in older individuals – a late-stage memory B cell (CD27^–^IgD^–^) that is often exhausted. ABCs secrete pro-inflammatory cytokines (like TNF-α, IFN-γ) and promote inflammaging. They are linked to higher autoimmune risk.
• Poor vaccine responses: Combination of above factors → elderly generate fewer high-affinity memory B cells after vaccination, contributing to rapid waning of immunity.
• B lymphocytes, which produce antibodies, also undergo age-related changes.

B Cells

• There is a quantitative decline in the output of new B cells. The bone marrow of older adults produces fewer naïve B cells, and the peripheral pool shifts towards memory B cells. As a result, the B cell receptor (BCR) repertoire shrinks – older individuals have fewer unique antibody sequences available. Studies using BCR sequencing find that many B cell clones are overrepresented (clonal expansions), indicating less diversity. This reduction in diversity means the ability to respond to new pathogens or vaccines with novel antibodies is compromised.
• The quality of the antibody response also degrades. In younger people, when B cells encounter an antigen (like in a vaccination), they undergo processes in lymph node germinal centers: class-switch recombination (changing from IgM to IgG, IgA etc.) and somatic hypermutation with selection (to increase affinity of antibodies). In older adults, germinal center reactions are less efficient. There’s less class switching and affinity maturation. So, an elderly person’s plasma cells might churn out more low-affinity IgM and fewer high-affinity IgG than a younger person’s in response to the same vaccine. This directly translates to lower antibody titres and neutralisation capacity. For example, after influenza vaccination, older adults not only produce fewer antibodies, but the ones they produce bind the virus less strongly, so they’re less protective. This is a key reason for reduced vaccine efficacy.
• With aging, there’s also a loss of self-tolerance in B cells, leading to more autoantibodies in circulation. Normally, central tolerance (in bone marrow) and peripheral tolerance eliminate or control self-reactive B cells. An important gene called AIRE (Autoimmune Regulator) helps present self-antigens in the thymus to eliminate self-reactive lymphocytes. In older adults, the expression of AIRE and other tolerance mechanisms wane. Also, the decline of regulatory T cell function can remove checks on autoreactive B cells. So, we often detect more autoantibodies in elders – for instance, higher titres of ANA (antinuclear antibodies) are common in elderly without overt autoimmune disease, indicating a general drift towards autoimmunity. This sets the stage for conditions like late-onset lupus or rheumatoid arthritis, which indeed correlate with these immune changes.
• Researchers have identified Age-Associated B Cells (ABCs) as a distinct subset that increases with age. These are typically CD21^low^ or CD27^-IgD^- B cells – basically an exhausted memory B cell phenotype. They tend to express the transcription factor T-bet. Functionally, ABCs are not great at mounting antibody responses; instead, they often secrete inflammatory cytokines such as TNF-α and IFN-γ. They can also present antigen and influence T cells, often skewing towards pro-inflammatory responses. ABCs have been implicated in autoimmune pathology too – they accumulate in autoimmune diseases like lupus and rheumatoid arthritis and can produce autoantibodies. In older individuals, the rise of ABCs is thought to inhibit new B cell development (they release factors that suppress the bone marrow’s B lymphopoiesis) and promote inflammaging. In essence, the B cell compartment tilts toward a pro-inflammatory, less adaptable state.
• All these factors contribute to weaker vaccine responses on the B cell side. After a vaccine, elderly have fewer naive B cells to recruit, less robust germinal center activity, and a higher proportion of their B cells might be these less responsive ABCs or other memory cells that are nearing senescence. It’s not surprising that, for example, antibody levels after the COVID mRNA vaccines were substantially lower in patients above 80 compared to young adults, and they waned faster. Clinically, it underlines why strategies like booster doses and higher antigen doses are used, and why entirely new approaches (like adjuvants or cytokine therapies) are being explored to help older individuals mount a better B cell response.

Taken together, the adaptive immune system in aging (both T and B cells) becomes like a library full of old books (memory cells) but missing new books (naïve cells) and some pages (diversity), with some books misfiled (autoimmunity) or too worn out to read (senescent cells). Now, after detailing these changes, let’s visualise how these alterations manifest and connect to clinical outcomes.

Inflammatory Aging Clock

Notably, to the right, it explicitly shows “Cell Proportion Clocks” and “Inflammatory Aging Clock (iAge)”. The cell proportion clock graphs depict how deviations in certain cell types correlate with age (for example, the increase of effector T cells and decrease of naive T cells that we talked about). The iAge clock, shown as a neural network diagram, emphasises a deep-learning approach using inflammatory markers to predict aging – recall that CXCL9 was a key biomarker in iAge. In the figure, CXCL9 is explicitly illustrated (middle row, showing a normal cell turning into an “aged immune cell” emitting CXCL9). In fact, experimental suppression of CXCL9 was shown to reduce vascular aging in mice, highlighting it as not just a marker but a potential driver of tissue aging.

Key Biomarkers of Immune Aging

• Inflammatory markers: Chronic elevation of IL-6, TNF-α, and CRP is common in older adults (“inflammaging”) and predicts frailty and mortality. High ferritin (an acute phase protein) can also indicate an inflammatory aging state.
• Neutrophil–Lymphocyte Ratio (NLR): Simple index of systemic inflammation. Tends to increase with age; higher NLR is linked to frailty and cardiovascular risk in the elderly.
• CD4/CD8 T-cell ratio: A low or inverted CD4:CD8 ratio is a classic immunosenescence marker. In very old populations, CD4:CD8 < 1 is associated with poorer survival (often connected with CMV infection driving CD8 expansion).
• Senescent T cell burden: Proportion of CD8^+^CD28^- (or CD57^+^) T cells – higher values reflect an aged immune profile and correlate with vulnerability to infections and cancer
• Immunoglobulin profiles: Elevated autoantibodies (e.g. ANA) or poor vaccine antibody response titers can serve as functional biomarkers of immune age.

Inflammatory cytokines and proteins

We can assess “immune age” in patients using various biomarkers, from routine lab tests to specialised immunologic assays.

Perhaps the most straightforward markers of inflammaging are circulating levels of pro-inflammatory cytokines like Interleukin-6 (IL-6) and Tumour Necrosis Factor-alpha (TNF-α), as well as acute phase reactants like C-reactive protein (CRP).

In healthy young individuals, these are low at baseline; in many older adults, IL-6 and CRP are mildly elevated chronically. Studies have shown IL-6 levels in the highest quartile for age are strongly associated with frailty, disability, and mortality. For example, IL-6 is sometimes nicknamed the “cytokine for gerontologists” because of how well it correlates with age-related decline. CRP similarly tends to creep up with age (even absent acute infection). Another marker is ferritin, often elevated in older adults – partly due to inflammation and also chronic subclinical iron dysregulation – it can act as an additional gauge of inflammatory load. A high ferritin in an elder without another cause sometimes flags an underlying inflammatory condition or just high inflammaging status. These markers are easily measured in blood and, while not specific, provide a window into the chronic inflammatory “set point” of an individual.

• Neutrophil–Lymphocyte Ratio (NLR): This is calculated from a complete blood count (CBC) – it’s the absolute neutrophils divided by absolute lymphocytes. It’s a cheap, integrative marker of inflammation: infections or stress increase neutrophils and decrease lymphocytes (due to cortisol effect), raising the NLR. Chronically, older adults often have a higher NLR than younger folks. Research has linked higher NLR with frailty and all-cause mortality in elderly populations, even after adjusting for diseases. For instance, in one study of exceptionally long-lived individuals, those with lower NLR tended to live longer, implying it might reflect better preserved immune homeostasis. Clinically, if I see an 85-year-old patient with a persistently high NLR (say >5) without an acute illness, it suggests some ongoing inflammatory or stress state and perhaps a more “aged” immune system.
• CD4/CD8 T-cell ratio: This ratio historically has been used in contexts like HIV, but in aging research it’s also informative. A normal CD4:CD8 ratio in a young healthy person is around 2:1. In immunosenescence, we often see this ratio invert or drop significantly (e.g. 1:1 or lower). That typically happens because of expansion of CD8^+ memory T cells (often due to CMV) and loss of CD4^+ naïve cells. An inverted CD4/CD8 ratio was part of the “Immune Risk Profile” identified in longitudinal studies of the very old – those who had CD4:CD8 < 1 had higher 2-year mortality in the Swedish OCTO/NONA studies. It’s not a perfect predictor, but it’s a handy snapshot: if I measure T subsets in a 90-year-old and find a low CD4:CD8 ratio, I suspect their immune system has a heavy burden of memory CD8 cells (likely CMV-driven) and reduced reserve. That correlates with frailty and less reserve to handle new immunologic stress.
• Senescent T cell burden: More specifically, labs or research studies can measure the percentage of T cells that lack CD28 or that express markers like CD57 and KLRG1, which accumulate on late-stage T cells. A high percentage of CD8^+CD28^- T cells is a biomarker of immune aging – in octogenarians this can be a large fraction of total CD8 cells, whereas in young adults it’s near zero. This metric correlates with vulnerability: for example, one study showed adults with higher CD28^- T cell counts responded less well to influenza vaccination and had higher rates of infections. Some advanced flow cytometry panels use a combination (like the IMM-AGE score proposed in research) to quantify these aging T cell changes.
• B cell/antibody markers: We might also consider markers like immunoglobulin levels or repertoire measures. Notably, autoantibodies such as ANA (anti-nuclear antibody) or rheumatoid factor often appear in elderly individuals – low titres might be benign, but rising titres can indicate immune dysregulation. The presence of multiple autoantibodies in an older person without clinical autoimmune disease suggests loss of tolerance, a sign of immune aging. Additionally, one can measure the vaccine response as a functional biomarker: for instance, checking titers after pneumococcal or shingles vaccine. If an older patient fails to mount antibodies where expected, it’s a practical indicator of immunosenescence in action.

In practice, these biomarkers can help identify older patients at risk. For example, an older adult with high IL-6, high CRP, inverted CD4:CD8 ratio, and high NLR likely has significant inflammaging and immunosenescence – they might benefit from closer monitoring, aggressive management of risk factors, or even experimental interventions to boost immunity. Now, beyond these individual measures, scientists have created composite biomarkers and “immune age clocks” to integrate multiple parameters, which we will discuss next.

Advanced Immune Age Metrics (“Clocks”)

• Inflammatory Aging Clock (iAge): A composite index derived via AI that uses levels of inflammatory markers to predict biological age. CXCL9 is a key contributor – high CXCL9 levels push iAge older, correlating with multi-morbidity.
• Immune Cell Proportion Clock: Measures deviations in blood immune cell percentages with age. Example: increased CD8^+^ effector memory T and NK cells, decreased naïve T and B cells form an “immune ageotype” profile. These patterns can predict an individual’s immune age and relate to epigenetic aging.
• Single-cell “Immune Age” clocks: New clocks use single-cell RNA sequencing of immune cells. They capture subtle shifts (e.g. unique naive vs. memory T cell gene signatures) and identified unusual immune profiles in centenarians (potential protective patterns).
• Epigenetic adjustments: Specialized epigenetic clocks (like Extrinsic Epigenetic Age index) incorporate immune cell composition. The IntrinClock is a clock less affected by immune cell distribution changes, offering a purer measure of cellular aging independent of cell type shifts
• Metabolomic signatures: Patterns of metabolites (e.g. heightened glycolysis byproducts, altered amino acids) in plasma can indicate immune aging. Untargeted metabolomics linked certain metabolic changes with high inflammation in older adults (potential biomarkers for immune aging status).

The Inflammatory Aging Clock, or iAge

Beyond basic biomarkers, researchers have developed composite “clocks” to quantify immune aging similarly to epigenetic aging clocks.

 Developed by Furman and colleagues at Stanford, iAge uses a machine learning model on a panel of inflammatory markers (cytokines, chemokines) to produce a single “immune age” score. In a large cohort, they found CXCL9 – a T-cell chemoattractant – to be the strongest marker driving iAge. Essentially, iAge higher than chronological age means one’s immune system exhibits a profile of an older person. People with high iAge were shown to have more multimorbidity, frailty, and poor cardiovascular function. Interestingly, in experimental settings, reducing CXCL9 made aged endothelial cells behave more youthfully, hinting that iAge isn’t just correlational but might capture causal factors of aging. For clinicians, iAge isn’t commercially available yet, but it points toward a future where a blood test of a few cytokines might stratify patients by “immune age” and risk for age-related diseases.

• The immune cell proportion clock is another approach. Researchers (like Alpert et al.) tracked how the percentages of various immune cells change with age. In youth, immune cell proportions (naive vs memory T cells, B cells, monocytes, etc.) stay within relatively tight ranges. In older individuals, these proportions diverge widely – some older folks have extreme expansions of certain cell types. By modeling these changes, they created a clock: for example, a typical pattern of an older immune system is more CD8^+ effector-memory T cells and CD56^+CD16^+ NK cells, and fewer naive CD4^+, naive CD8^+, and B cells. They even described distinct “immune ageotypes” – subtypes of immune aging where certain cell expansions dominate. An interesting insight was epigenetic age differences: naive T cells appear “younger” in their DNA methylation age compared to effector T cells from the same person – by ~15-20 years!. This means part of why older people have higher epigenetic age is because their blood has more older cell types. They responded by designing clocks like IntrinClock (intrinsic epigenetic age not confounded by cell counts). But practically, an immune cell proportion clock could be implemented via routine flow cytometry to get an immune age score.
• Single-cell immune age clocks take this further by looking at gene expression in thousands of individual immune cells. For example, a clock by Zhu et al. integrated single-cell transcriptomic data from PBMCs. They found that changes in specific subpopulations – like naive CD8 T cells and memory CD4 T cells – were key indicators of biological age. In supercentenarians (100+ years old), the single-cell data showed unusual patterns like retention of certain naive-like cell subsets, which might contribute to their extreme longevity. The promise here is that single-cell approaches can catch nuanced shifts (maybe a rare subset emerging or disappearing) that bulk measures miss. However, this is more in the research realm currently due to complexity and cost.
• Epigenetic clocks for the immune system: While not a direct immune measure, it’s worth noting that standard epigenetic aging clocks (like Horvath’s clock, PhenoAge, etc.) are heavily influenced by immune cell DNA (since blood is commonly used). The Extrinsic Epigenetic Age Acceleration (EEAA) measure was designed to incorporate immune parameters (it includes components for naive T cell counts, etc.). There’s also research on an “immunosenescence clock” that merges epigenetic and immune data for better prediction of age-related immune decline. The mention of Tomusiak et al. 2024 in the references is exactly about developing an epigenetic clock resilient to changes in immune cell composition, which highlights how important the immune system is in measuring aging.
• Metabolomic signatures: Finally, beyond cells and cytokines, our metabolites change with age and reflect immune-metabolic health. For instance, one study found that older adults with high expression of inflammasome genes had abnormal nucleotide metabolism profiles in blood. Others saw that certain amino acid or lipid metabolites shift with aging and chronic viral infections. For example, a chronic viral infection in older adults can cause alterations in glutamine and phospholipid metabolism. Integrating metabolomics with immune data can improve how we gauge immune aging. In fact, a 2023 report (Fu et al., EMBO Rep) talks about “metabolomics meets systems immunology”, underlining that a metabolomic age index might correlate with immune function decline. While these metabolomic markers aren’t in clinical use, they contribute to our holistic understanding and might become future biomarkers (e.g., an ‘immune age metabolite panel’ in serum).

In summary, there’s intense interest in quantifying immune aging with composite measures. These advanced metrics – iAge, cell clocks, etc. – are still emerging tools but they reinforce what we know from simpler markers and could guide interventions (for example, a very “immune-old” 65-year-old might benefit from early targeted therapies to rejuvenate immunity, as we’ll discuss next).

A recap on the clinical implications 

• Frailty and immune aging: Patients with advanced immunosenescence often overlap with frailty (weakness, weight loss) – immune markers (like IL-6) are components of frailty indices.
• Infections: Need for vigilant prevention (vaccinations, infection control) in older patients due to slower immune responses. Use of high-dose flu vaccines, conjugated pneumococcal vaccines, etc. becomes standard.
• Cancer surveillance: Immune decline might warrant more frequent screening in elderly (while balancing life expectancy) since reduced surveillance can allow malignancies to grow
• Autoimmune manifestations: Atypical autoimmunity (e.g. polymyalgia rheumatica, late-onset lupus) should be considered in older patients – immune aging can unmask these; check inflammatory markers if new symptoms like arthralgias.
• Personalised interventions: Immune age biomarkers could help identify which older adults are biologically “immunologically old” vs “young” – guiding intensity of interventions (e.g. who might benefit from immune-boosting therapies or closer monitoring).

Overview on Frailty

Before we move on to interventions, let’s synthesise how these immune aging changes inform clinical practice:

• Frailty: Immune aging and frailty are tightly linked. Frailty is a geriatric syndrome of vulnerability (with signs like unintentional weight loss, exhaustion, slow walking speed, low grip strength). Chronic inflammation (IL-6, CRP) is part of the biological underpinning of frailty. In fact, high IL-6 and low vitamin D are sometimes used in frailty indices. If we identify an older patient with evidence of significant immunosenescence/inflammaging (like high cytokines, poor vaccine response), that patient likely either is frail or at risk of becoming frail. It suggests we should institute comprehensive geriatric care – nutrition, physical therapy, etc. – to maintain their reserve.
• Infection prevention: Knowledge that an 80-year-old’s immune system responds sluggishly is why we emphasize vaccinations and other preventive measures in geriatrics. For example, influenza vaccination – guidelines call for high-dose or adjuvanted flu shots in ≥65-year-olds to overcome immunosenescence. Shingles vaccine (recombinant zoster vaccine) is recommended because latent VZV can reactivate easily when T cell surveillance wanes. Pneumococcal vaccines (both PCV13/15 and PPSV23) are advised to reduce bacterial pneumonia risk, given older adults’ diminished adaptive responses. Even with vaccines, older patients mount less protection, so we often add layers: e.g. booster doses (like COVID-19 boosters offered more frequently to 65+). In hospitals and nursing homes, there’s recognition that older folks might not manifest classic fever or leukocytosis in infection (due to immune blunting). So having a high index of suspicion and perhaps lower thresholds for initiating antibiotics is common – for instance, an older patient with slight confusion might get evaluated for UTI or pneumonia even if no fever. Infectious disease protocols increasingly consider host age (for example, for post-exposure prophylaxis decisions or duration of treatment, knowing older patients may clear infections slower).
• Cancer surveillance: As mentioned, immune surveillance declines, which probably contributes to the steep increase in cancer incidence with age. While screening guidelines focus on chronological age, an argument can be made for adjusting screening based on biological age. If someone is 75 but biologically very “young” immunologically, they might live 15-20 more years and benefit from continued screening (e.g. colonoscopy, mammograms). On the other hand, an immunologically “old” 70-year-old might be at risk for cancers but also might not tolerate treatment – a delicate balance. Understanding immune aging might also lead to immunoprevention strategies – e.g. could we vaccinate or otherwise bolster the immune system to prevent cancer? (There are examples like the zoster vaccine also reducing burden of zoster-related strokes via immune effect, or BCG vaccine being explored for broad immune activation in elderly). At minimum, clinicians remain vigilant for malignancies in older patients and maybe more so if they have a history of severe immunosenescence (like an HIV-positive elder with a low CD4 count or someone on long-term immunosuppressants – analogous situations).
• Autoimmune manifestations: Immune aging can present somewhat paradoxically as autoimmune diseases in older patients. We are seeing more recognition of late-onset autoimmune diseases. For example, late-onset rheumatoid arthritis tends to have a more acute onset and equal gender incidence, likely tied to immune aging changes. Polymyalgia rheumatica and giant cell arteritis are conditions almost exclusively seen over age 50, peaking in the 70s – these may be driven by aging of the immune system (e.g., the loss of tolerance and pro-inflammatory environment attacking arteries and joints). As clinicians, when an older patient comes with new inflammation (e.g., elevated ESR/CRP, joint pains, or weird systemic symptoms), we consider these diagnoses – something that might not be on the differential in a younger adult. It’s important to not attribute everything to “just aging” – sometimes it is aging immune system causing a treatable condition. Immune aging markers could, in the future, help differentiate healthy aging vs pathological inflammation requiring therapy.
• Personalised interventions: If we have ways to measure immune age (as we discussed: maybe an iAge test or a cell subset panel), we could stratify patients. Perhaps in the future, a 70-year-old with a youthful immune profile might follow standard guidelines, whereas one with an advanced immune age might get more aggressive interventions to preserve immunity. We already do a bit of this informally: e.g. checking varicella-zoster immunity in older adults – those who lack antibodies might get vaccinated to prevent shingles. Or measuring CMV serostatus in an older person considered for immunosuppressive therapy; a CMV-positive older patient might be at higher risk for issues, influencing prophylaxis. As our toolkit expands, we might check an “immune age score” and if it’s high, consider interventions like IL-6 blockers or senolytics experimentally to reduce inflammaging, or ensure they get extra monitoring during immunosuppressive treatments or surgery.

This recap underscores the broad relevance of immune aging – it informs preventive care, acute care, and chronic disease management in geriatrics. Now, the critical question: what can we do about it? We will move into the strategies to intervene in immune aging, from medications to lifestyle.

Strategies to Mitigate Immune Aging: Pharmacological

• mTOR inhibitors (e.g. rapamycin/everolimus): Target nutrient-sensing pathways to rejuvenate immunity. In trials, low-dose everolimus improved elderly vaccine responses (20% higher influenza antibody titres) and reduced infections. Ongoing studies (e.g. TORCH trial) testing if rapalogs enhance overall immune function in aging.
• Metformin: A diabetes drug with geroprotective effects. A pilot in older adults showed metformin use was associated with less T-cell exhaustion after flu vaccination. Metformin may dampen inflammation (via AMPK activation) and is being studied in the TAME trial for multi-system aging delay.
• Senolytics: Drugs that selectively clear senescent cells (e.g. Dasatinib + Quercetin). Experimental but promising – clearing senescent immune cells in mice reduced inflammaging and improved response to vaccines. Human trials are underway to see if periodic senolytics improve immune profiles in elders.
• Immune modulators:
  • IL-7 therapy: Recombinant IL-7 can boost thymopoiesis and expand naïve T cells in older adults (trials show increased CD4^+^ and CD8^+^ naive counts).
  • Checkpoint inhibitors: In non-cancer settings, low-dose PD-1/PD-L1 blockade is theorised to reinvigorate exhausted T cells in chronic infections or aging (not routine, high risk of autoimmunity).
  • Cytokine/Interleukin supplementation: e.g. IL-2 in ultra-low doses to expand regulatory T cells (being tried to counter inflammaging in some studies).
• Other agents: Zinc supplementation (if deficient) improves immune function and lowers infection risk; Vitamin E showed improved NK cell function in elderly in past trials; Thymic peptides (like thymosin α1) are used in some countries to enhance T-cell immunity in aged individuals (mixed evidence).

How to slow, halt or reverse aspects of immune aging

We’ll now discuss pharmacological interventions that aim to slow, halt, or reverse aspects of immune aging. This is a cutting-edge area of translational research, often overlapping with the field of geroscience (targeting fundamental aging processes to treat age-related diseases).

• mTOR inhibitors: The mTOR pathway is a central regulator of cell growth and metabolism, and it appears to drive aging when overactive. Rapamycin (Sirolimus) and its analogues (e.g. Everolimus) inhibit mTOR and have been shown to extend lifespan in multiple animal models. In humans, an exciting result came from the Mannick et al. trials. In a 2014 Science Translational Medicine study, a 6-week course of an mTOR inhibitor combination in people over 65 led to a ~20% boost in antibody responses to flu vaccine. Following that, a phase 2b trial of everolimus (RAD001) in the elderly showed reduced incidence of infections over the following year, though one subsequent larger trial had mixed results (no significant reduction in infections overall). Despite that, these trials proved the principle that targeting mTOR can enhance immune function in older humans: participants on everolimus had increased vaccine responses and less T-cell exhaustion. So, rapalogs might become the first true “immune anti-aging” drugs if further trials (like the ongoing RESCUE and PREVENT trials) confirm benefits. Clinically, these are not yet standard, but some clinicians might consider off-label low-dose rapamycin in biologically aged patients (this is experimental and needs careful monitoring for side effects like metabolic effects or mouth ulcers). Importantly, dosing and scheduling (e.g. once weekly dosing) seem critical to get immune benefits without undue immune suppression.
• Metformin: This widely used oral diabetes medication has emerged as a candidate geroprotector. Epidemiologically, diabetics on metformin have shown lower cancer rates and improved survival compared to those on other therapies, hinting at something beyond glucose control. In terms of immune aging, metformin has anti-inflammatory effects (AMPK activation, reducing NF-κB signaling). A 2023 study showed that older adults on metformin had reduced expression of exhaustion markers on T cells after influenza infection/vaccine. There’s also evidence it can restore some responsiveness in old T cells. The ongoing TAME (Targeting Aging with Metformin) trial is looking at multi-system health outcomes in non-diabetics. If positive, we might soon consider metformin in non-diabetic older patients for general healthspan improvement, including immune health. It’s generally safe and inexpensive, which is attractive. At present, some geriatricians already prescribe a low dose to very high-risk patients (e.g., metabolic syndrome individuals) hoping to tap into its anti-aging properties.
• Senolytics: Given that senescent cells and their SASP drive inflammaging, senolytics aim to remove senescent cells. In mice, periodic dosing of senolytic drugs (like the combination of the chemotherapy Dasatinib and the flavonoid Quercetin) cleared senescent cells and dramatically improved tissue function in multiple organs, and even enhanced vaccine responses in older mice by reducing background inflammation. Human trials are in early stages (small studies in diabetic kidney disease and idiopathic pulmonary fibrosis used senolytics and showed reduced inflammatory markers). If senolytics can be shown to reduce inflammaging in people, it could be revolutionary – imagine a pill that one takes maybe once a month that clears out senescent immune cells and resets inflammation to a younger state. However, these drugs have potential side effects (dasatinib can cause blood count suppression, etc.), so they’re still experimental. A safer senolytic or more targeted approach (maybe using senolytic antibodies directed at senescence markers) is a hot research area.
• Immune modulators:
  • IL-7 therapy: IL-7 is a cytokine critical for T-cell development and survival. In aging, IL-7 levels decline, and providing low-dose IL-7 can “wake up” the T cell production. Trials in humans have shown that IL-7 can increase the count of naive T cells in older individuals or immune-depleted patients. In one study, older adults given recombinant IL-7 showed an expansion of their CD4 and CD8 naive T cells by fostering thymic output. This is like giving a “growth factor” to the immune system. It’s not yet an approved therapy for aging, but IL-7 is used experimentally in settings like post-transplant or HIV to rebuild T-cell pools. We might see it repurposed for immunosenescence (e.g., to help an older patient recover immune function after chemotherapy or severe infection).
  • Checkpoint inhibitors in aging: Checkpoint blockade (anti-PD-1, anti-PD-L1 drugs) revolutionised oncology by reinvigorating exhausted T cells to fight cancer. Theoretically, small doses could reinvigorate an aging immune system’s exhausted T cells as well. But the risk is causing autoimmunity or hyperinflammation. This is not clinically done due to risks, but research in mice suggests a short pulse of PD-1 blockade in very old mice improved their response to vaccines (with careful titration). It’s a risky approach, likely not needed if other gentler ways can achieve similar ends.
  • Cytokine supplementation: Another idea is supplementing beneficial cytokines that decline with age. For example, low-dose IL-2 therapy has been tried to expand regulatory T cells (Tregs) in older individuals to counter autoimmunity and inflammaging. Some small trials in autoimmune disease in older patients use ultra-low dose IL-2 to boost Treg numbers and function, which might indirectly reduce inflammatory damage. GM-CSF is another factor (it can boost myeloid cell function) – interestingly, sargramostim (GM-CSF) in very low doses was tested in Alzheimer’s patients to stimulate microglia; results are preliminary but showed some immune activation and possibly cognitive benefit. These are not mainstream yet.

Other agents and supplements

• • Zinc: Micronutrient deficiencies can exacerbate immune aging. Zinc is crucial for thymic function and white cell counts. Many older adults have marginal zinc deficiency (due to malnutrition or malabsorption). Trials supplementing zinc in elderly have demonstrated reduced infection rates and improved T cell-mediated response. For instance, a study gave nursing home residents zinc and saw fewer pneumonia events. Ensuring adequate zinc (and other nutrients like Vitamin D, selenium) is a basic, evidence-backed step.
  • Vitamin E: High-dose vitamin E (200–800 IU) was studied in the 1990s in older adults – one trial showed enhanced NK cell activity and improved response to respiratory infections in nursing home residents. However, subsequent analyses on mortality risks of high-dose Vitamin E made its use controversial. Now we aim for a balanced diet or a multivitamin rather than high-dose E specifically.
  • Thymic peptides: In some countries, Thymosin alpha-1 (a thymic peptide) is approved to treat chronic infections and as an immune stimulant. It is thought to enhance T cell maturation and dendritic cell function. Some studies in hepatitis and cancer in older patients suggested it can improve immune parameters and outcomes. While not widely used in mainstream medicine globally, it’s an interesting tool that some longevity clinics use off-label for immune senescence. Its efficacy in general aging is not conclusively proven, but it has a good safety profile.
  • Others: There are exploratory compounds like FMT (fecal microbiota transplant) from a young donor – in mouse models, giving an old mouse the gut microbiome of a young mouse improved its immunity and reduced inflammaging. It’s far from standard practice in humans except for C. diff infection, but it’s conceptually intriguing (since microbiome influences systemic inflammation). Also, aspirin or statins with their anti-inflammatory properties might have some effect on inflammaging, although they come with their own risk considerations.

A Toolbox

In practice, none of these drugs are yet a magic bullet for aging. But they represent a toolbox being assembled.

A decade from now, the management of an 80-year-old might routinely include one of these interventions if proven safe and effective – e.g. a periodic rapalog dose to boost vaccine responses and reduce infections, or a senolytic course to reduce chronic inflammation and improve organ function. Right now, outside of research, the solid steps are ensuring adequate micronutrients, possibly using metformin if indicated, and for specific high-risk patients, there is off-label use of rapamycin in some circles (though not officially recommended yet).

The message to take home is that immune aging can be targeted – it’s not entirely immutable. Next, let’s cover lifestyle measures, which can be as powerful as drugs and are accessible to all older patients.

Strategies to Mitigate Immune Aging: Lifestyle

• Exercise: Regular moderate exercise is a potent immune booster in elderly. It increases neutrophil function (better chemotaxis, phagocytosis), enhances NK cell cytotoxicity, and enlarges the T-cell repertoire. Studies found older adults who exercise have more recent thymic emigrant T cells and longer telomeres in leukocytes. Even initiating a walking program in late life can improve vaccine responses and lower systemic inflammation.
• Diet and Caloric Restriction: Balanced diets (like Mediterranean diet) rich in antioxidants and omega-3s help lower inflammation. Caloric restriction (CR) by ~10–15% has shown benefits – a 2-year human trial of mild CR improved thymus function and reduced inflammatory markers. Intermittent fasting or time-restricted feeding may modulate the gut microbiome and reduce pro-inflammatory monocytes.
• Probiotics and gut health: The gut microbiome influences immunity. Six-month probiotic supplementation in elderly showed reduced frequency of CD8^+^CD28^- senescent T cells and improved CD4:CD8 ratios. Probiotics also enhanced responses to influenza vaccine and lowered risk of respiratory infections. A fibre-rich diet similarly supports a diverse microbiome that produces anti-inflammatory metabolites.
• Stress reduction & Sleep: Chronic stress and poor sleep accelerate immune aging (via cortisol and sympathetic overactivation). Mind-body interventions (yoga, tai chi, meditation) in older adults were linked to lower IL-6 and higher vaccine antibody responses in some studies. Prioritising 7–8 hours of sleep and treating sleep apnea helps lower systemic inflammation.
• Smoking cessation & Alcohol moderation: Smoking causes premature immune aging (elevates inflammatory cytokines, impairs neutrophils). Stopping smoking can partially reverse this over time. Heavy alcohol use also depresses immune function – moderation or abstinence will improve neutrophil and T-cell activity over months.

Focus on lifestyle factors

Lifestyle factors are incredibly important – sometimes even more than medications – in modulating immune aging.

• Exercise: It’s often said that exercise is the closest thing we have to a true anti-aging therapy. In terms of immunity, studies show that moderately active older adults have immune profiles similar to much younger people. Mechanistically, exercise increases circulation and shear stress which can stimulate the bone marrow and thymus. A study using isotopic labeling showed that exercise induces the release of new naive T cells from the thymus in older adults (basically “waking up” thymic tissue a bit). Exercise, especially resistance and aerobic combination, also lowers chronic inflammation – muscle contractions release anti-inflammatory cytokines like IL-10 and myokines that reduce TNF levels. For example, a controlled trial found that a 12-month aerobic exercise program in older women significantly decreased their CRP and IL-6 levels. Moreover, neutrophil and macrophage function are acutely improved after bouts of exercise – improved chemotaxis and microbicidal activity. Long-term, fit older adults have better vaccine responses – one study on influenza vaccination showed those who did regular moderate exercise had higher antibody titres and fewer winter infections than sedentary peers. Telomere studies also famously found that Masters athletes (70+ who train regularly) had longer leukocyte telomeres, signifying a more “youthful” immune cell population. The key is consistency and moderation – overtraining can actually suppress immunity transiently, but moderate training (e.g., brisk walking 30 min a day, plus some strength exercises twice a week) is ideal.
• Diet & Caloric Restriction: Diet influences immune health through nutrient availability and impacts on metabolism and gut microbiota. An anti-inflammatory diet (Mediterranean pattern – high in fruits, vegetables, whole grains, olive oil, fish) has been associated with lower levels of inflammatory markers in older adults and better cognitive and immune outcomes. For instance, omega-3 fatty acids from fish oil can reduce inflammatory prostaglandins and have been shown to enhance B cell function in some trials. Caloric restriction (CR) is one of the most robust interventions to extend lifespan in animals; in humans, we can’t do extreme CR, but a mild CR (10% calorie reduction) was trialed in the CALERIE study. They observed improved thymic fat volume (the thymus appeared more functional on MRI) and reduced C-reactive protein in participants – hinting that even modest CR can rejuvenate aspects of immunity. The practicality is difficult (people find CR hard to maintain), but some adopt intermittent fasting (IF) regimens which can mimic some CR effects. IF (like 16:8 fasting/eating window, or 5:2 weekly fasting) has been shown to reduce pro-inflammatory monocytes and improve insulin sensitivity. By changing feeding patterns, IF can alter the gut microbiome favorably and induce cellular clean-up processes (autophagy) which might help clear senescent cells or dysfunctional components. In summary, encouraging a nutrient-rich but not excessive diet, potentially with controlled caloric intake, may slow immune aging.
• Gut health and Probiotics: There’s growing recognition that the gut microbiome shapes the immune system. With age, microbiome diversity tends to decrease and more pro-inflammatory bacterial strains may dominate (partly from diet changes, medications, etc.). Probiotic supplements (or probiotic-rich foods like yogurt, kefir, fermented vegetables) can help reintroduce beneficial bacteria. A notable study gave elderly volunteers a combination of Lactobacillus and Bifidobacterium strains for 6 months. They found a reduction in the percentage of senescent (CD28-null) T cells and an increase in the CD4/CD8 ratio, basically a partial reversal of immunosenescence markers. Additionally, those on probiotics had a better response to the flu vaccine (more folks achieved protective antibody titres). Also, their rate of catching common colds and gut infections was lower during the study. It suggests the gut microbiome can be tuned to improve systemic immunity. Apart from probiotics, simply increasing dietary fibre (e.g. through fruits, veg, whole grains) provides prebiotics that nourish good gut bacteria, which then produce short-chain fatty acids that have anti-inflammatory effects on the body. Many older patients suffer from constipation or poor diet, so focusing on fibre and fermented foods can meaningfully impact their immune health.
• Stress management and Sleep: Chronic psychological stress (like caregiving stress or bereavement) has measurable effects on immunity. For example, caregivers of Alzheimer’s patients (a high-stress group) were found to have poorer vaccine responses and higher IL-6 levels compared to matched controls. Stress elevates cortisol and adrenaline, which over time suppress aspects of immune function (like slowing lymphocyte proliferation and skewing T cells towards an exhausted phenotype). Activities that reduce stress – meditation, tai chi, yoga, or even social support groups – have been shown in small studies to lower inflammatory markers and sometimes improve telomerase activity in immune cells. Sleep is another critical pillar: deep sleep is when the body produces a lot of growth hormone and does immune “housekeeping” (like consolidating memory and immune memory). Chronic sleep deprivation or disordered sleep (apnea) results in higher CRP and more activated innate immune cells at baseline. Interventions: encourage good sleep hygiene in older adults, treat conditions like sleep apnea (CPAP can reduce the chronic inflammation caused by nightly oxygen drops), and if needed, use short-term sleep aids or melatonin to normalise sleep cycles. Adequate sleep can boost vaccine responses – one study showed people who slept <5 hours the night after a vaccine had a significantly reduced antibody response. So for older patients, emphasising 7-8 hours of quality sleep is a simple “immune boost” strategy.
• No smoking and minimal alcohol: Smoking has a well-known association with immune alterations – smokers have higher levels of systemic inflammation, and their alveolar macrophages are overloaded with debris and less functional. Smoking also depletes vitamin C and other antioxidants, leading to more oxidative stress on immune cells. Quitting smoking even after decades leads to improvements: within 6 weeks, some NK cell activity returns and infection risk starts to drop. By a year or two, the risk of pneumonias and such goes down. Similarly, alcohol in excess is immunosuppressive (it can cause lymphopenia and liver damage that impairs immune protein synthesis). While 1 drink a day might be okay or even slightly anti-inflammatory (like red wine’s polyphenols), heavy drinking is detrimental. So advising older patients to stop smoking completely and keep alcohol to moderate levels (if any) is vital for their immune health.

As a case example: consider an 82-year-old woman who wants to stay healthy. We would encourage her to do gentle exercises like walking and resistance band training, eat a Mediterranean-style diet with appropriate calories, perhaps take a probiotic, get 7-8 hours of sleep, stay socially engaged to reduce stress (social isolation also correlates with higher inflammation), and avoid smoking/drinking. These measures in synergy can compress the period of immune decline, keeping her immune system “younger” than her chronological age. And they complement any medical interventions we might consider.

Now that we’ve covered how to measure and address immune aging with both drugs and lifestyle, let’s briefly look at what’s on the horizon – future directions and ongoing research that might soon translate to practice.

Emerging Therapies & Future Directions

• Vaccines and immune training: Development of special vaccines for older adults (higher antigen content, new adjuvants like TLR agonists) to better stimulate an aged immune system. E.g. an adjuvanted zoster vaccine (Shingrix) shows 90% efficacy even in 80-year-olds by overcoming immunosenescence.
• Plasma exchange/Rejuvenation: Trials on therapeutic plasma apheresis – removing & replacing a portion of aged plasma to eliminate pro-inflammatory factors (small studies like the Ambrosia trial hinted at reduced biological age markers). Also, young plasma transfusion is being explored for immune rejuvenation (in mice, young blood restores old immune cell function).
• Regenerative therapies: Thymus regeneration – e.g. GH+DHEA+metformin in the small TRIIM trial led to some thymic regrowth and improved naive T-cell counts. Future regenerative medicine might grow a bioengineered thymus or use thymic cytokines to boost T-cell production in seniors
• Organoid models for drug screening: Using “immune system in a dish” models – e.g. human tonsil organoids exposed to microgravity to mimic aging – to rapidly test interventions (gene knockouts, drug repurposing) that could rejuvenate immune responses. This could accelerate discovery of new immune anti-aging drugs.
• Multi-modal interventions: Ultimately, combinations may work best – e.g. a protocol that combines senolytics (to clear bad cells) + a rapamycin course (to enhance autophagy) + a personalised vaccine schedule + lifestyle coaching. Research will aim to find the right mix and timing to extend immune healthspan (years of good immune function).

Bridging geriatrics and cutting-edge biotechnology

The future of longevity strategies and tacking immune aging will include:

• Better vaccines for older people: Since traditional vaccines often underperform in elders, a lot of R&D is going into making vaccines more immunogenic for that age group. For example, Shingrix, the shingles vaccine, uses a strong adjuvant (AS01_B_) that essentially hyper-stimulates the innate immune system to overcome the sluggish response – that’s why it works so well even in 80-90 year-olds. We expect more vaccines with novel adjuvants: e.g. TLR agonists (to stimulate dendritic cells harder), or even cytokine adjuvants (IL-7 or IL-2 microdoses included to recruit T cells) being integrated into vaccines like influenza or next-gen COVID boosters. There’s also interest in trained immunity – giving agents that nonspecifically boost innate immune memory. For instance, some studies are using the BCG vaccine (originally for TB) in elderly to reduce unrelated infections; initial results (the ACTIVATE trial) showed fewer respiratory infections in BCG-vaccinated older adults, suggesting it “trained” their innate immunity. We might see recommendations in future where older adults get some immunostimulatory vaccine or agent yearly to broadly bolster their defenses (kind of like a tune-up).
• Plasma exchange and young plasma: This stems from fascinating parabiosis experiments where an old and young mouse share circulation – the old mouse’s tissues got younger. Now, human trials like Plasma exchange (where a portion of plasma is removed and replaced with saline/albumin) are being tested for Alzheimer’s and frailty. The idea is to dilute out pro-inflammatory cytokines and replace missing factors. A trial called PLASMA (in Alzheimer’s) suggested slight cognitive improvements, though it’s early. Conversely, giving young plasma transfusions to older individuals (basically transfusing factors present in young blood) is another concept. A small safety study gave young plasma to patients with mild Alzheimer’s – it showed some functional improvements (though no control group, so not definitive). If specific anti-aging factors in young blood (like certain growth factors) can be isolated, that’s even better – e.g. GDF11 was once thought to be a “youth factor” that could rejuvenate heart and muscle; it’s controversial, but this line of research is actively looking for circulating molecules that reverse immune aging. We might envision in future a therapy where an older patient receives an infusion of a cocktail of beneficial proteins derived from young plasma or recombinant sources to reset immune function periodically.
• Thymus regeneration: The thymus is such a bottleneck that regrowing it could significantly restore youthful immunity. The TRIIM trial (Thymus Regeneration, Immunorestoration and Insulin Mitigation) was a very intriguing pilot: 9 men aged 51-65 were given growth hormone + DHEA + metformin for one year. They saw evidence of thymic fat reduction on MRI and increased naive T cell counts, plus – remarkably – a reduction in epigenetic age by about 2.5 years on average. Though it was a tiny study, it shows regeneration is possible. Larger studies are being planned. Other approaches might involve stem cell therapy or tissue engineering (maybe growing a thymus organoid and implanting it, or using thymic epithelial cell transplants). Gene therapy might even be used to upregulate thymopoiesis-related factors (like FOXN1, a gene important for thymus growth that declines with age). Another concept is using peptides like thymic stromal lymphopoietin (TSLP) to try to boost thymic output. These are all in experimental phases.
• Immune organoids for drug testing: The figure 2 from Wu et al. (2025) illustrated an approach where researchers take human tonsil tissue or PBMCs and culture them as organoids (mini lymphoid organs in a dish). Then they apply an “accelerated aging perturbation” such as simulated microgravity (which mimics some aging stress on cells) to induce features of immune aging quickly. After that, they can test various interventions on these organoids and do multi-omic analysis (transcriptomics, etc.) to see what reverts the aging signatures. This is like rapidly modeling immune aging and potential rejuvenation in the lab. It could drastically shorten the time needed to identify promising drugs. For instance, they could knock out certain genes (Candidate Functional Gene KO, as in the figure) to see if it makes old immune cells behave youthfully – maybe discovering new drug targets. Or test libraries of drug repurposing candidates on the organoid (like maybe a common blood pressure medication might unexpectedly boost immune function – we wouldn’t know without testing). So, this platform is a powerful discovery engine that might yield the next generation of geroprotective drugs.
• Combination therapies: Most likely, the future will not rely on one single magic drug but a combination approach. Just as HIV is managed with multiple drugs (ART therapy) targeting different aspects, immune aging might be tackled from multiple angles concurrently: for example, imagine a 70-year-old undergoes a senolytic treatment to clear out senescent cells, then takes rapamycin weekly to boost autophagy and immune surveillance, plus ensures optimal nutrition and maybe an immune-modulating supplement (like a probiotic or a cytokine) – all tailored to their needs. It could be seasonal or cyclic: e.g., a rapamycin course leading up to flu season to augment vaccine efficacy, or senolytic treatment every few years to reduce the accumulation of dysfunctional cells. The combinations will be refined by ongoing and future clinical trials.

All in all, the recognition that immune aging is modifiable is gaining ground. As our population ages, these interventions could vastly improve quality of life by reducing infections, improving responses to vaccines (like ensuring a 85-year-old responds to a new pandemic vaccine as well as a 40-year-old would), and lowering the burden of chronic inflammatory diseases. The next decade will likely see some of these strategies move from trials to clinics.

With that optimistic view of what’s coming, let’s conclude our discussion with key take-home points and how we as clinicians can integrate this knowledge now and in the near future.

Conclusion

• The immune system undergoes predictable aging changes (immunosenescence – weaker adaptive responses, and inflammaging – heightened baseline inflammation). These drive increased infection risk, malignancies, and inflammatory diseases in older adults
• Key biomarkers (like iAge, cytokine levels, and immune cell ratios) allow us to gauge an individual’s “immune age” beyond their years – useful for identifying high-risk patients and tracking intervention effects
• Maintaining immune health is a cornerstone of healthy aging: strategies such as exercise, proper diet, vaccination, and micronutrient supplementation are evidence-based measures every older adult should pursue
• Emerging interventions give hope that we can rejuvenate aspects of the aging immune system – early trials of drugs like rapamycin and metformin, as well as lifestyle interventions, show improved vaccine responses and reduced inflammation in seniors
• As clinicians, adopting a proactive approach (“immune geroprotection”) – optimising lifestyle, ensuring vaccinations, and potentially using future therapies to boost immune function – can extend healthspan and resilience in our aging population. By unlocking and monitoring these immune biomarkers, we move towards personalised longevity medicine where 80 might become the new 60 in immune terms

In closing

1. Immune aging is real and impacts patient outcomes: It’s not just a theoretical concept – we see its effects daily in the hospital and clinic. Recognising that an 80-year-old’s fever response may be blunted or their vaccine needs are different is directly tied to immunosenescence. Similarly, inflammaging links to many chronic diseases; for example, the overlap of high IL-6 levels with both heart disease and frailty. As medical professionals, being aware of a patient’s potential immune age can guide our vigilance and management (for instance, being aggressive with a seemingly mild infection in an older person).
2. We have tools to assess immune age: From simple (CBC ratios, CRP) to advanced (multi-omic clocks), these biomarkers give us an edge in identifying patients who are biologically older or younger than their chronological age. A patient in their 70s with low inflammatory markers and robust lymphocyte populations might be managed differently (perhaps fewer restrictions, more confidence in vaccine efficacy) compared to one whose labs scream “inflammaging” (where we’d be more cautious and perhaps intervene more intensively). In future, we might routinely get an “immune age panel” in geriatrics clinics.
3. Healthy lifestyle is non-negotiable: It’s heartening that some of the most effective interventions are within our patients’ reach without a prescription. We should counsel older patients that it’s never too late to adopt healthier habits – studies show people who start exercising in their 70s still gain immune benefits. Community programs for seniors (like tai chi classes or walking groups) can double as social engagement and exercise, tackling two aging issues at once. Nutrition advice and managing weight also pay dividends for their immune system. Even things like getting an annual flu shot can be framed as a way to “exercise” the immune system (some data suggests repeated vaccination helps maintain responsiveness).
4. Medical interventions are evolving: We discussed some pharmaceuticals that, while not yet standard, could soon augment our arsenal. It’s plausible that in 5-10 years, we will have approved therapies specifically to boost immune function in older adults – perhaps a drug that one takes before the winter season to rev up immunity. As these emerge, clinicians should stay informed and carefully weigh risks vs benefits (because any immune booster can have downsides like autoimmunity if not managed well – it’s a balance). The current off-label exploration by some (like rapamycin use in biohackers) should be approached cautiously and ethically in practice until larger studies confirm safety.
5. Personalised geriatric care with immune focus: The ultimate goal is to increase healthspan, the period of life spent in good health. By addressing immune aging, we can reduce the years of morbidity due to infections, cancer, and organ damage. It aligns with geriatric medicine’s mission of compressing morbidity. As we treat older patients, thinking in terms of immune system optimization – just like we think of optimising blood pressure or glucose – can become part of routine care. For example, an annual “immune check-up” could become a thing, where we review their vaccination status, check inflammatory markers, and adjust any interventions (like perhaps start a short metformin course or ensure they’re doing resistance training).

In summary, the immune system’s aging is a key driver of how we age overall. But it’s not a one-way street; research shows we can measure it, we can slow it, and to some extent, we might even reverse elements of it. As doctors, incorporating this knowledge means we can better protect our older patients and help them live not just longer, but with a higher quality of life, free from the preventable consequences of immune decline. Thank you for your attention – let’s continue to monitor this exciting field and apply these insights in our practice for the benefit of our aging communities.

References

1. Wu, F., Mu, W.-C., Markov, N. T., et al. (2025). Immunological biomarkers of aging. Journal of Immunology, 214(5), 889–902. (Open Access, CC BY 4.0)
2. Murphy, S. (2025). Immune Aging Unlocked: The Key Biomarkers of Longevity. Longevity Insider (Substack newsletter)
3. Sayed, N., et al. (2021). An inflammatory aging clock (iAge) based on deep learning tracks multimorbidity, immunosenescence, frailty and cardiovascular aging. Nature Aging, 1(7), 598–615
4. Mannick, J. B., et al. (2014). mTOR inhibition improves immune function in the elderly. Science Translational Medicine, 6(268), 268ra179
5. Martin, D. E., et al. (2023). The effect of metformin on influenza vaccine responses in nondiabetic older adults: a pilot trial. Immunity & Ageing, 20(1), 18
6. Hearps, A. C., et al. (2012). Aging is associated with chronic innate immune activation and dysregulation of monocyte phenotype and function. Aging Cell, 11(5), 867–875
7. Alpert, A., et al. (2019). A clinically meaningful metric of immune aging derived from high-dimensional longitudinal monitoring. Nature Medicine, 25(3), 487–495
8. Franceschi, C., & Campisi, J. (2014). Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci, 69(Suppl 1), S4–S9.
9. Fulop, T., et al. (2020). Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes? Frontiers in Immunology, 11, 604.
10. Weyand, C. M., & Goronzy, J. J. (2016). Aging of the immune system. Mechanisms of Ageing and Development, 160, 1–3. (Overview of immune aging mechanisms)

Speaker notes

Key references include the primary review by Wu et al. (2025), which provided much of the detailed content, and the Substack article by Dr. Murphy for practical insights. Also listed are significant studies such as Sayed et al. on the iAge clock and Mannick et al. on mTOR inhibition in elderly. These sources validate the points made in the lecture. Clinicians are encouraged to consult these works for deeper reading.*